ORCHID PHARMA TO MERGE DHANUKA LABS; EYES ₹1,500 CR REVENUE TARGET

• ✅ NCLT Chennai approves merger of Orchid Pharma and Dhanuka Labs • 📅 Appointed date for merger fixed at April 1, 2024; effective date subject to regulatory filings • 📈 Combined entity targets ₹1,400-1,500 crore revenue and ₹200-250 crore EBITDA • 🔄 Dhanuka Labs shareholders to receive 161 Orchid Pharma shares (FV ₹10) for every 5 Dhanuka shares (FV ₹100) • 🤝 Merger expected to unlock operational synergies, improve efficiency and strengthen market positioning • 👥 All assets, liabilities and employees of Dhanuka Labs to be transferred to Orchid Pharma

ORCHID PHARMA LIMITED

← Back to feed